Treatment Decision Making in Early-Stage Prostate Cancer

This study has been completed.
Sponsor:
Collaborator:
U.S. Army Medical Research and Materiel Command
Information provided by:
Georgetown University
ClinicalTrials.gov Identifier:
NCT00196781
First received: September 12, 2005
Last updated: January 11, 2010
Last verified: January 2010
  Purpose

We plan to test the effectiveness of a recently developed computer-based program that is designed to improve patient knowledge about prostate cancer treatments. It is also designed to help men clarify their values using a computer-based 'decision aid.' A decision aid gives patients tools to help them understand their own values and how these values may be related to their choice of different forms of therapy for prostate cancer. In order to test the effectiveness of the decision aid, men will be assigned on a chance basis to receive either 1) the computer program that includes the information about prostate cancer treatments alone, or 2) the computer program that contains both the information and the decision aid. We expect that men in decision aid group will be more active in their treatment decision and will have improved knowledge, quality of life, and satisfaction with the treatment decision relative to men who only receive the information.


Condition Intervention Phase
Localized Prostate Cancer
Behavioral: CD-ROM-based prostate cancer treatment education
Behavioral: CD-ROM-based prostate ca treatment education+decision tools
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment Decision Making in Early-Stage Prostate Cancer: Evaluation of Computer Based Patient Education and an Interactive Decision Aid

Resource links provided by NLM:


Further study details as provided by Georgetown University:

Primary Outcome Measures:
  • treatment satisfaction, quality of life, prostate cancer knowledge at 1, 6, and 12 months post random assignment [ Time Frame: one, six, and one year follow-up assesments ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • shared decision making at 1, 6, and 12 months post random assignment. [ Time Frame: one, six and one year follow-up assesments ] [ Designated as safety issue: No ]

Enrollment: 168
Study Start Date: September 2002
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: the Information + Decision Aid group Behavioral: CD-ROM-based prostate ca treatment education+decision tools
The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
Other Names:
  • Prostate Cancer treatment education
  • Decision Tools
Active Comparator: Information Only group Behavioral: CD-ROM-based prostate cancer treatment education
The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
Other Name: Prostate Cancer Treatment Education

Detailed Description:

Background: There is a controversy in the medical community surrounding the utility of treatment options for clinically localized prostate cancer. Although several options are available for management of localized prostate cancer, no option is clearly superior to others. The main therapeutic options for localized prostate cancer include radical prostatectomy (RP), radiation therapy (RT; external beam radiation or brachytherapy), and expectant management (EM) or "watchful waiting." The American Urological Association, after a structured review of the available literature, concluded that there is insufficient evidence to clearly recommend RP, RT, or EM. They recommended that factors such as life expectancy, current health, and patient preference for therapeutic options be considered in the treatment decision. Since the survival benefits of the different management strategies are as of yet uncertain, and men's preferences for outcomes of therapy may influence the decision regarding management choice, men should be informed of potential outcomes and should be encouraged to examine their own values in deciding upon a management strategy for their prostate cancer.

Objective: The primary goal is to evaluate a method of patient education that is designed to provide treatment-related information and to help men clarify their preferences and values via a recently developed computer-based decision aid. We expect that men randomized to the decision aid condition will be more active in their treatment decision and will have improved patient outcomes relative to men assigned to the Information only condition.

Specific Aims. The specific aims are: 1) To evaluate the relative impact of providing newly diagnosed patients with computer-based prostate cancer treatment information vs. providing patients with the information plus an interactive decision-aid on a) shared decision-making practices and b) patient outcomes (decisional satisfaction, quality of life, knowledge), 2) To explore the mechanisms by which the decision aid impacts on SDM and patient outcomes, and 3) To identify men who are most and least likely to benefit from the education plus decision-aid intervention.

Study Design: Men will be accrued at the time of their biopsy and those with a positive biopsy result will receive the intervention following notification of the diagnosis but prior to their initial meeting with the urologist in which treatment options are discussed. Participants will be followed at one, six and twelve months post-intervention. The primary outcomes include patient outcomes (knowledge, quality of life, and decisional satisfaction) and shared decision making (SDM) practices.

Relevance In many areas of medicine, including treatment of localized prostate cancer, there has been a rapid expansion of research that has resulted in a growing number of diagnostic and treatment options that are available to physicians and patients. In many cases, there are several effective and viable treatment options, but randomized clinical trials assessing treatment effectiveness have not yet been completed. Although the availability of different options will undoubtedly be beneficial in the long run, at present it creates a difficult decision for individuals and physicians who are faced with the choices for which no best answer is known. The proposed study is designed to assist patient through this decision, by providing information and helping them to consider their values.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligibility criteria include: 1) ability to speak English, 2) absence of cognitive impairment that would limit participation in the study. 3) Diagnosis of localized prostate cancer. Participants will not be limited by age.

Exclusion Criteria:

  • Men who have already made a treatment decision.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00196781

Locations
United States, District of Columbia
Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
Sponsors and Collaborators
Georgetown University
U.S. Army Medical Research and Materiel Command
Investigators
Principal Investigator: Kathryn L. Taylor, Ph.D. Georgetown University
  More Information

No publications provided

Responsible Party: Kathryn L. Taylor, PhD, Principal Investigator, Georgetown University Medical Center
ClinicalTrials.gov Identifier: NCT00196781     History of Changes
Other Study ID Numbers: DAMD17-02-1-0062
Study First Received: September 12, 2005
Last Updated: January 11, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Georgetown University:
prostate cancer treatment
medical decision making
informed decision making
shared decision making
decision aid
patient education

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on October 16, 2012